AnxietyPhase 2NCT02427568
MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
A Phase 2 study testing Midomafetamine HCl and Therapy in people with Anxiety, run by Resilient Pharmaceuticals at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy? Researchers will compare people… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anxiety
- What is being tested?
- Midomafetamine HCl and Therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 18 participants
- Where
- 1 siteUnited States
- Study dates
- 14 May 2015to 17 May 2018
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with life-threatening cancer or non-dementing neurological illness, which can be ongoing or in remission, but with a possibility of recurrence
- Prognosis of at least nine months life expectancy from the time of screening
- Have anxiety as a result of facing their illness
- Are at least 18 years old
- Are willing to refrain from taking any psychiatric medications during the study period;
- Are willing to commit to medication dosing, experimental sessions, follow-up sessions, and to complete evaluation instruments
Show all 12Show fewer
- Are willing to remain overnight at the study site after each experimental session until after the integrative session occurring the next morning
- Must sign a medical release for the investigators to communicate directly with their therapist and doctors;
- Are willing to select up to three observers who will complete observer measures of subject attitudes and behavior
- Negative pregnancy test if able to bear children and agree to use effective birth control
- Are proficient in speaking and reading English
- Agree to have all psychotherapy sessions recorded to audio/video.
Who cannot join
- Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of birth control;
- Weigh less than 48 kg
- Are abusing illegal drugs
- Are unable to give adequate informed consent
- Upon review of past, current drugs/medication must not be on or have taken a medication that is exclusionary
- Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study
- Have used "Ecstasy" (material represented as containing MDMA) at least once within twelve months of enrollment.
Trial locations and contacts
1 site in 1 country.
United States1 site
Offices of Philip Wolfson MD
San Anselmo, California, 94960
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy?
Researchers will compare people receiving placebo with therapy to people receiving MDMA-assisted therapy.
- Participants will undergo three non-drug preparatory therapy sessions before their first blinded session of MDMA or placebo with therapy.
- Each medication session will be followed by three non-drug integrative therapy sessions.
- After the second blinded medication session, participants receiving MDMA will complete a third open-label medication session.
- Participants who received placebo will be given the option to crossover and receive three sessions of assisted therapy.
Read the detailed description
This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study in 18 participants comparing the effects of MDMA-assisted therapy vs. placebo with therapy. Thirteen participants were randomized to the active dose condition of 125 mg of MDMA HCl (plus an optional supplemental dose of 62.5 mg MDMA HCl) with therapy and five participants were randomized to the placebo with therapy condition. The study consisted of two blinded experimental sessions of MDMA-assisted therapy or placebo with therapy, each session lasting six to eight hours and scheduled two to four weeks apart. Each participant was unblinded one month after their second experimental session in Stage 1. After unblinding, participants receiving MDMA were to complete a third open-label experimental session of MDMA-assisted therapy and participants who originally received placebo had the opportunity to cross over to open-label Stage 2 and receive active MDMA-assisted therapy in 3 sessions.
The primary objective of the study is to assess changes in trait anxiety in subjects receiving active dose MDMA compared to those receiving placebo as measured by State-Trait Anxiety Index (STAI) Trait scores from Baseline to the Primary Endpoint (one month after the second experimental session).
- Conditions
- Anxiety
- Being tested
- Midomafetamine HCl, Placebo, Therapy
- Keywords
- Anxiety, MDMA, Life-threatening illness, Therapy, midomafetamine
- Medical subject headings
- Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Midomafetamine HClDrug
Also called 3,4-methylenedioxymethamphetamine, Midomafetamine, MDMA
Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.
PlaceboDrug
Also called Inactive placebo
Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.
TherapyBehavioural
Manualized therapy
| Study group | Role | What they receive |
|---|---|---|
| Placebo with therapy | Placebo comparator | Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose. Receives: Drug: Placebo; Behavioral: Therapy |
| MDMA-assisted therapy (125 mg) | Experimental | 125 mg midomafetamine HCl administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg. Receives: Drug: Midomafetamine HCl; Behavioral: Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.
The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Primary Endpoint STAI Trait Score
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.
The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.
Measured: One month post-2nd experimental session
Secondary outcomes (9)
Change in STAI State Score From Baseline to Primary Endpoint
The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 ("Not at all") to 1 ("Very much so"), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.
The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint
The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint
The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)
Change in MADRS Score From Baseline to Primary Endpoint
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, > 34 severe depression. Higher scores indicate greater severe depression.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint
The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint
The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint
The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from "strongly disagree" (score of 1) to "strongly agree" (score of 7), with higher scores indicating more positive attitudes toward death.
The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint
The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 "almost never" to 5 "almost always." The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses.
A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety.
Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2015 (estimated)
- Study start14 May 2015
- Primary completion25 Apr 2017
- Study completion17 May 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AnxietyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Resilient Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Philip Wolfson, MD, Principal investigator, Private Practice
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02427568
- Sponsor's protocol ID
- MDA-1
- Status last verified
- May 2025
- First submitted
- 13 Apr 2015
- Last updated
- 5 Jun 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: We will share outcome data appearing in any published reports upon request.
Publications
Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E, Carlin SC, Sola E, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020 Nov 24;10(1):20442. doi: 10.1038/s41598-020-75706-1.
PubMed 33235285
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
- ClinicalTrials.gov ID
- NCT02427568
- Acronym / sponsor ID
- MDA-1
- Conditions
- Anxiety
- Keywords
- Anxiety, MDMA, Life-threatening illness, Therapy, midomafetamine
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Resilient PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 14 May 2015 (actual)
- Primary completion
- 25 Apr 2017 (actual)
- Study completion
- 17 May 2018 (actual)
- First posted
- 28 Apr 2015 (estimated)
- Results
- Posted 2 Aug 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy?
Researchers will compare people receiving placebo with therapy to people receiving MDMA-assisted therapy.
- Participants will undergo three non-drug preparatory therapy sessions before their first blinded session of MDMA or placebo with therapy.
- Each medication session will be followed by three non-drug integrative therapy sessions.
- After the second blinded medication session, participants receiving MDMA will complete a third open-label medication session.
- Participants who received placebo will be given the option to crossover and receive three sessions of assisted therapy.
Detailed description
This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study in 18 participants comparing the effects of MDMA-assisted therapy vs. placebo with therapy. Thirteen participants were randomized to the active dose condition of 125 mg of MDMA HCl (plus an optional supplemental dose of 62.5 mg MDMA HCl) with therapy and five participants were randomized to the placebo with therapy condition. The study consisted of two blinded experimental sessions of MDMA-assisted therapy or placebo with therapy, each session lasting six to eight hours and scheduled two to four weeks apart. Each participant was unblinded one month after their second experimental session in Stage 1. After unblinding, participants receiving MDMA were to complete a third open-label experimental session of MDMA-assisted therapy and participants who originally received placebo had the opportunity to cross over to open-label Stage 2 and receive active MDMA-assisted therapy in 3 sessions.
The primary objective of the study is to assess changes in trait anxiety in subjects receiving active dose MDMA compared to those receiving placebo as measured by State-Trait Anxiety Index (STAI) Trait scores from Baseline to the Primary Endpoint (one month after the second experimental session).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo with therapy | Placebo comparator | Drug: Placebo, Behavioral: TherapyInactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose. |
| MDMA-assisted therapy (125 mg) | Experimental | Drug: Midomafetamine HCl, Behavioral: Therapy125 mg midomafetamine HCl administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Diagnosed with life-threatening cancer or non-dementing neurological illness, which can be ongoing or in remission, but with a possibility of recurrence
- Prognosis of at least nine months life expectancy from the time of screening
- Have anxiety as a result of facing their illness
- Are at least 18 years old
- Are willing to refrain from taking any psychiatric medications during the study period;
Key exclusion criteria (7 listed)
- Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of birth control;
- Weigh less than 48 kg
- Are abusing illegal drugs
- Are unable to give adequate informed consent
- Upon review of past, current drugs/medication must not be on or have taken a medication that is exclusionary
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Midomafetamine HClAlso: 3,4-methylenedioxymethamphetamine, Midomafetamine, MDMATwo sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart. | Drug | MDMA-assisted therapy (125 mg) |
| PlaceboAlso: Inactive placeboTwo sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart. | Drug | Placebo with therapy |
| TherapyManualized therapy | Behavioural | MDMA-assisted therapy (125 mg), Placebo with therapy |
Primary outcome
Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive.
Primary Endpoint STAI Trait Score
Time frame: One month post-2nd experimental session
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.
9 secondary outcomes
Change in STAI State Score From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)
Change in MADRS Score From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 33235285Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E, Carlin SC, Sola E, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020 Nov 24;10(1):20442. doi: 10.1038/s41598-020-75706-1.
- Individual participant dataSharing planned: Yes. We will share outcome data appearing in any published reports upon request.
Related trials for Anxiety
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philip Wolfson, MD principal investigator
Private Practice
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Midomafetamine HCl and Therapy in people with Anxiety, run by Resilient Pharmaceuticals at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Aug 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint (time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02427568, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.